10-K: Lineage Cell Therapeutics Announces Separation and Consulting Agreement with Dr. Gary S. Hogge

Lineage Cell Therapeutics has entered into a separation, release, and consulting agreement with Dr. Gary S. Hogge, effective November 30, 2023, which includes separation benefits and a consulting period.

Summary

• Lineage Cell Therapeutics has reached a separation, release, and consulting agreement with Dr. Gary S. Hogge, whose employment terminated on November 30, 2023.
• Dr. Hogge will receive a lump sum payment of $412,485, equivalent to nine months of his base salary plus a prorated 2023 target bonus.
• Lineage will also cover 100% of Dr. Hogge's health insurance premiums under COBRA for up to nine months, or until he obtains new employer-sponsored health coverage.
• Dr. Hogge will provide consulting services to Lineage from December 4, 2023, to March 31, 2024, at a rate of $500 per hour, with a maximum liability for Lineage of $30,000.
• Dr. Hogge's outstanding equity awards will cease to vest as of the separation date, and his rights to exercise vested shares will be governed by the applicable equity plans.
• The agreement includes a general release of claims against Lineage and a waiver of rights under the Age Discrimination in Employment Act (ADEA), with a 7-day revocation period.
• Dr. Hogge is required to return all Lineage property and confidential information and is subject to non-disparagement and cooperation clauses.

Sentiment

Score: 7

Explanation: The document is neutral in tone, outlining the terms of a separation and consulting agreement. It is a standard business practice and does not indicate any significant positive or negative sentiment.

Positives

• The agreement provides Dr. Hogge with a financial package including a lump sum payment and health insurance coverage.
• Lineage secures Dr. Hogge's expertise through a consulting agreement for a defined period.
• The agreement includes a release of claims, which protects Lineage from potential future litigation.
• The consulting agreement allows for a smooth transition of Dr. Hogge's responsibilities.

Negatives

• Dr. Hogge's equity awards ceased vesting, which may be a negative for him.
• The consulting agreement is limited to a maximum of $30,000, which may limit the scope of services provided.
• The agreement includes a non-disparagement clause, which may limit Dr. Hogge's ability to speak freely about Lineage.

Risks

• The agreement includes a clause that Dr. Hogge will not be held liable for disclosing trade secrets to government officials for reporting violations of law.
• Dr. Hogge is required to notify Lineage if he provides services to a competitor or becomes employed full-time during the consulting period.
• Lineage has the right to terminate the consulting agreement immediately upon receipt of information regarding debarment, ineligibility, conviction, threat, or indictment of Dr. Hogge.
• Dr. Hogge is aware that Lineage may provide material non-public information to him and must comply with U.S. securities laws regarding the purchase or sale of securities.

Future Outlook

The document outlines the terms of the separation and consulting agreement, with no specific forward-looking statements about the company's future performance or guidance.

Management Comments

• Lineage wishes Dr. Hogge the best in his future endeavors.

Industry Context

This document is a standard separation and consulting agreement, common in the biotechnology industry when a senior executive departs. It ensures a smooth transition and protects the company's interests.

Comparison to Industry Standards

• The terms of the separation agreement, including the severance payment and COBRA coverage, are generally consistent with industry standards for executive departures.
• The consulting agreement is a common practice to retain expertise during a transition period.
• The inclusion of non-disparagement and confidentiality clauses is standard in such agreements to protect the company's reputation and intellectual property.

Management Changes

Stakeholder Impact

• Shareholders: The agreement provides clarity on the departure of a key executive and ensures a smooth transition.
• Employees: The agreement may impact employee morale, but the consulting agreement may provide some continuity.
• Management: The agreement outlines the terms of the transition and ensures the company's interests are protected.

Next Steps

• Dr. Hogge will provide consulting services to Lineage from December 4, 2023, to March 31, 2024.
• Lineage will make payments to Dr. Hogge as outlined in the agreement.
• Lineage will monitor Dr. Hogge's compliance with the terms of the agreement.

Key Dates

Keywords

separation agreement, consulting agreement, stock options, equity awards, COBRA, release of claims, non-disparagement, Lineage Cell Therapeutics, Gary S. Hogge, employment termination